FICHA FARMACOLÓGICA de anagrelide. Contiene la Monografía en distintos idiomas (de la Comunidad Económica Europea), así como la discusión científica que sustenta su aprobación terapéutica. Para acceder a la monografía en idioma español, hacer doble clik en la sigla (es) en la fila que se sitúa más abajo del centro de la página oficial. Cerasale. ABRIL 07, 2009.
abrir aquí:
EPARs for authorised medicinal products for human use - Xagrid
Active Substance
Anagrelide hydrochloride
International Nonproprietary Name or Common Name
Anagrelide
Pharmaco-therapeutic Group
Other Antineoplastic Agents
ATC Code
L01XX35
Therapeutic Indication:
Xagrid is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an
acceptable level by their current therapy. An at risk essential thrombocythaemia patient is defined by one or more of the following features: >60 years of age, or a platelet count >1000 x 109/l, or a history of thrombo-haemorrhagic events.
Date of issue of Marketing Authorisation valid throughout the European Union
16 November 2004
Orphan medicinal product designation date
29 September 2000
.png)
No hay comentarios:
Publicar un comentario